<DOC>
	<DOC>NCT02867605</DOC>
	<brief_summary>The purpose of this study is to evaluate whether oral HA35 supplementation changes the normal intestinal bacteria, increases intestinal protection, decrease intestinal inflammation and permeability, and to assess any health benefits and confirm the safety profile of HA35.</brief_summary>
	<brief_title>Human Pilot Study - HA35 Dietary Supplement for Promoting Intestinal Health</brief_title>
	<detailed_description />
	<criteria>BMI 1925 (lean), and BMI 3035 (obese) Age 1845 years old Willingness to take oral supplement and adhere to study requirements Diabetes Oral antibiotics within 4 weeks of study initiation History of cardiac disease, and medications for cardiac disease Use statins and antihypertensive drugs Inflammatory bowel disease including irritable bowel syndrome History of intestinal surgery, excluding hernia repair and appendectomy Active cancer diagnosis (except skin cancer) Chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor antagonists) Immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic NSAIDs) Vegetarian or vegan diet7 Abnormal liver or kidney function as measured by routine serum chemistry testing Severe anemia or significant white blood cell or platelet abnormalities No additional blood or blood product donations during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>